Presented by:

Sponsored by:

Now available on demand. Sign up to view

The Beginning of the End: Immunoprofiling Coming of Age


Originally aired; April 27, 2017

As immuno-oncology makes major inroads into the battle against cancer, the need for effective prognostic and predictive biomarkers is growing rapidly, as response rates continue in the 10 – 30% range and the menu of options, including combinations, grows at an accelerating pace.  We hypothesize that understanding the status of the immune system at the site of the cancer will be critical to the tailoring of immunotherapy combinations and for developing effective biomarkers to predict response to immunotherapy, since response depends on characteristics of both the cancer and of the immune system cells in-situ. Multiplex immunofluorescence is the most effective and efficient way to identify specific immune cell types and their location and state of activation in the tumor microenvironment, and to assess check-point expression, all at the same time. This is highly beneficial for exploring immune evasion mechanisms, finding potential biomarkers for assessing the mechanism of action and predicting response, and for potentially tracking response.
This webcast will provide a brief overview of multiplex immunofluorescence methods and then present results from a recent study demonstrating the prognostic power of assessing the composition and relationships of cells in the tumor microenvironment in-situ in FFPE tissue sections. These results provide insights into how this information could be used to stratify patients for enrollment on clinical trials, evaluate drug mechanisms of action and potentially identify patients in need of aggressive therapy. Ultimately, this capability should accelerate the development of immuno-oncology agent combinations and improve outcomes for patients with cancer.

During the webcast you will:

  • Gain a clearer understanding of multiplex immunofluorescence and how to characterize cell-level immuno-biology in intact FFPE tissue sections
  • See experimental evidence of the real-world application of multiplexing and how it can be applied to study the tumor microenvironment
  • Have the opportunity to ask questions live during the broadcast!

Webcast sponsor retains sole responsibility for content.

Dr. Bernie Fox
Chief of the Laboratory of Molecular and Tumor Immunology
Providence Portland Medical Center
View Biography
Dr. Jayshan Carpen
Nature Research
View Biography

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)